¼¼°èÀÇ ½ÉÀå À絿±âÈ­ Ä¡·á(CRT) ½ÃÀå º¸°í¼­(2025³â)
Cardiac Resynchronization Therapy Global Market Report 2025
»óǰÄÚµå : 1703065
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 200 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,265,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,056,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,846,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

½ÉÀå À絿±âÈ­ Ä¡·á(CRT) ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â µ¿¾È °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2029³â±îÁö 6.8%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î 87¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾ÈÀÇ ¼ºÀåÀº ½ÉºÎÀü ¹× ½ÉÀå ÁúȯÀÇ À¯º´·ü Áõ°¡, ³ëÀÎ Àα¸ Áõ°¡, ½ÉÇ÷°ü ÁúȯÀÇ ÀÌȯÀ² Áõ°¡, CRT Ä¡·áÀÇ Çʿ伺, ½É¹ÚÁ¶À²±â ¹× Á¦¼¼µ¿±â Ä¡·áÀÇ °³¼±, CRT Ä¡·á¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡ µî¿¡ ±âÀÎÇÏ´Â °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ±âÁ¸ ½É¹ÚÁ¶À²±â¿¡ ´ëÇÑ CRT-D ÀåÄ¡ äÅÃ, ÷´Ü ±â¼ú ÅëÇÕ, CRT Ä¡·á È®´ë, ÀΰøÁö´É ÅëÇÕ, ¸Ó½Å·¯´× äÅà µîÀ» µé ¼ö ÀÖ½À´Ï´Ù.

½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ½ÉÀå À絿±âÈ­ Ä¡·á(CRT) ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ½ÉÇ÷°ü Áúȯ(CVD)Àº ½ÉÀå°ú Ç÷°ü¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ´Ù¾çÇÑ ÁúȯÀ» Æ÷ÇÔÇϸç, °í·ÉÈ­, °Ç°­¿¡ ÇØ·Î¿î »ýȰ½À°ü, Èí¿¬, ÁÂ½Ä »ýȰ, ½Ä½À°ü Àå¾Ö µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ CVD ¹ß»ý·üÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ½ÉÀå À絿±âÈ­ Ä¡·á(CRT)´Â µ¿±âÈ­µÈ Àü±â ÀÚ±ØÀ» ÅëÇØ ½ÉÀå ¼öÃàÀÇ ÇùÀÀ·ÂÀ» °³¼±ÇÔÀ¸·Î½á ½ÉºÎÀü°ú °°Àº Áõ»óÀ» Ä¡·áÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 9¿ù ¹Ì±¹ ¹Ì³×¼ÒŸÁÖ º¸°Ç±¹ ÀÚ·á¿¡ µû¸£¸é, 2023³â ¹Ì³×¼ÒŸÁÖ ¼ºÀÎÀÇ ¾à 30%°¡ °íÇ÷¾ÐÀ» ¾Î°í ÀÖÀ¸¸ç, ¾à 140¸¸ ¸íÀÌ °íÇ÷¾ÐÀ» ¾Î°í ÀÖÀ¸¸ç, 2022³â¿¡´Â °íÇ÷¾Ð¼º ÁúȯÀÌ ¹Ì³×¼ÒŸÁÖ¿¡¼­ 14,225¸íÀÇ »ç¸ÁÀ» ÃÊ·¡ÇÒ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖ½À´Ï´Ù. Àüü »ç¸ÁÀÚÀÇ ¾à 28%¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌó·³ ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ½ÉÀå À絿±âÈ­ Ä¡·á(CRT) ½ÃÀå ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

ÀÇ·áºñ ÁöÃâ Áõ°¡´Â ½ÉÀå À絿±âÈ­ Ä¡·á(CRT) ½ÃÀå È®´ëÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÇコÄɾî ÁöÃâÀº ƯÁ¤ ±â°£ µ¿¾È ÇコÄÉ¾î »óǰ ¹× ¼­ºñ½º¿¡ ´ëÇÑ ÃÑ ÁöÃâÀ» ÀǹÌÇϸç, ÀϹÝÀûÀ¸·Î ±¹°¡ ¶Ç´Â ±â°ü Â÷¿øÀÇ ÁöÃâÀ» ÀǹÌÇÕ´Ï´Ù. ÀÇ·á¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡´Â ½ÉÀå À絿±âÈ­ Ä¡·á(CRT) ºÐ¾ßÀÇ ¿¬±¸ °³¹ßÀ» ÃËÁøÇÏ¿© ±â¼ú ¹ßÀü, Ä¡·á Á¢±Ù¼º Çâ»ó, ÀÇ·á ½Ã½ºÅÛÀÇ º¸´Ù Á¾ÇÕÀûÀÎ Á¢±ÙÀ» ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 5¿ù ¿µ±¹ Åë°èûÀº 2021³â ¿µ±¹ÀÇ ÃÑ ÀÇ·áºñ ÁöÃâÀº 3,672¾ï 5,000¸¸ ´Þ·¯(2,807¾ï ÆÄ¿îµå)·Î ¸í¸ñ»ó 9.4%, ½ÇÁú 9.7% Áõ°¡ÇßÀ¸¸ç, ±× Áß ÀǾàǰ ÁöÃâÀº 518¾ï 4,000¸¸ ´Þ·¯(396¾ï ÆÄ¿îµå)¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óÇß½À´Ï´Ù. 2021³â¿¡´Â ¿¹¹æ ÀÇ·á¿¡ ´ëÇÑ ÁöÃâµµ ±ÞÁõÇÏ¿© 459¾ï 3,000¸¸ ´Þ·¯(351¾ï ÆÄ¿îµå)¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¶ÇÇÑ 2024³â 9¿ù, ¹Ì±¹¿¡ º»»ç¸¦ µÐ ABA Ä¡·á ¼­ºñ½º¸¦ Á¦°øÇÏ´Â Å©·Î½º ¸®¹ö Å×¶óÇÇ(Cross River Therapy)´Â ¹Ì±¹ Á¦¾à¾÷°èÀÇ ¸ÅÃâÀÌ 5,500¾ï ´Þ·¯¿¡ À̸£·¶À¸¸ç, 2021³â ¹Ì±¹ÀεéÀÌ ÀǾàǰ¿¡ 5,769¾ï ´Þ·¯¸¦ ÁöÃâÇß´Ù°í º¸°íÇß½À´Ï´Ù. ¿¹Ãø¿¡ µû¸£¸é ÀÌ ÁöÃâÀº 2025³â±îÁö 6050¾ï-6,350¾ï ´Þ·¯·Î Áõ°¡ÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. °á°úÀûÀ¸·Î ÀÇ·áºñ ÁöÃâ Áõ°¡´Â ½ÉÀå À絿±âÈ­ Ä¡·á(CRT) ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ½ÅÇü Äڷγª¹ÙÀÌ·¯½º, ±×¸®°í °æ±âȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°/±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀå ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Cardiac resynchronization therapy (CRT) is a treatment for heart failure aimed at synchronizing the contractions of the heart's ventricles. This therapy utilizes a biventricular pacemaker to administer electrical impulses to the heart muscle, thereby promoting a more coordinated rhythm of ventricular contractions. It has the potential to alleviate symptoms of heart failure, such as shortness of breath and fatigue, while also enhancing overall cardiac function.

The primary types of cardiac resynchronization therapy include cardiac resynchronization therapy (CRT)-defibrillator and cardiac resynchronization therapy (CRT)-pacemaker. A cardiac resynchronization therapy (CRT) defibrillator is a medical device designed to regulate heartbeats and deliver electrical shocks when irregular heart rhythms occur. These devices are utilized across various age groups, including patients below 44 years, 45-64 years, 65-84 years, and those aged above 85 years, by hospitals, cardiac care centers, and ambulatory surgical centers.

The cardiac resynchronization therapy market research report is one of a series of new reports from The Business Research Company that provides cardiac resynchronization therapy market statistics, including cardiac resynchronization therapy industry global market size, regional shares, competitors with a cardiac resynchronization therapy market share, detailed cardiac resynchronization therapy market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac resynchronization therapy industry. This cardiac resynchronization therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cardiac resynchronization therapy market size has grown strongly in recent years. It will grow from $6.29 billion in 2024 to $6.74 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to growth in the geriatric population, an increased incidence of heart failure, growth in investments in R&D for CRT device innovation, increased awareness about the therapy's benefits, physician training programs, and competitive landscape dynamics.

The cardiac resynchronization therapy market size is expected to see strong growth in the next few years. It will grow to $8.77 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to the increasing prevalence of heart failure and cardiac disorders, growth in the geriatric population, a higher incidence of cardiovascular diseases, the need for CRT therapy, improvements in pacemakers and defibrillator treatment, and increasing awareness about CRT therapy. Major trends in the forecast period include the adoption of CRT-D devices over traditional pacemakers, the integration of advanced technology, expansion of CRT therapy, the integration of artificial intelligence, and the adoption of machine learning.

The rising prevalence of cardiovascular diseases is expected to drive the growth of the cardiac resynchronization therapy (CRT) market. Cardiovascular diseases (CVD) encompass a range of conditions affecting the heart and blood vessels. The incidence of CVD is increasing due to factors such as aging populations, unhealthy lifestyles, high tobacco use, sedentary behavior, and poor dietary habits. Cardiac resynchronization therapy helps treat conditions like heart failure by improving the coordination of the heart's contractions through synchronized electrical impulses. For example, in September 2024, data from the Minnesota Department of Health, a US-based state health agency, revealed that approximately 30% of adults in Minnesota reported having high blood pressure in 2023, affecting nearly 1.4 million people. In 2022, hypertensive diseases were a contributing cause in 14,225 deaths in the state, accounting for almost 28% of all fatalities. As such, the growing prevalence of cardiovascular diseases is driving the demand for cardiac resynchronization therapy market.

The growing healthcare expenditure is expected to drive the expansion of the cardiac resynchronization therapy (CRT) market. Healthcare expenditure refers to the total spending on healthcare goods and services over a specific period, typically on a national or institutional level. Increased investment in healthcare can foster research and development in the field of cardiac resynchronization therapy, leading to advancements in technology, improved access to therapy, and a more comprehensive approach to healthcare systems. For example, in May 2023, the UK's Office for National Statistics reported a 9.4% nominal increase and a 9.7% practical increase in healthcare spending. In 2021, the UK's total healthcare spending was $367.25 billion (£280.7 billion), with pharmaceutical costs accounting for $51.84 billion (£39.6 billion). Spending on preventative care also surged in 2021, reaching $45.93 billion (£35.1 billion). Additionally, in September 2024, Cross River Therapy, a US-based provider of ABA therapy services, reported that the US pharmaceutical industry generated $550 billion in revenue, with Americans spending $576.9 billion on medicine in 2021. Projections suggest this spending will rise to $605-$635 billion by 2025. As a result, the increasing healthcare expenditure is driving the growth of the cardiac resynchronization therapy market.

Leading companies in the cardiac resynchronization therapy market are concentrating on the development of implantable devices to enhance treatment outcomes for heart failure patients. Implantable devices in CRT synchronize the contractions of the heart's ventricles, improving pumping efficiency and managing heart failure symptoms. For instance, MicroPort Scientific Corporation launched the GALI SonR cardiac resynchronization therapy and defibrillation device (CRT-D) and the Navigo 4LV left ventricular pacing leads in Japan in February 2024. This innovative CRT-D device incorporates the first and only CRT hemodynamic sensor, designed to automatically optimize patients on a weekly basis, even during physical activity, thus ensuring real-life optimization. The clinically proven SonR algorithm has demonstrated a 35% reduction in the risk of heart failure hospitalization, contributing to the well-being and safety of CRT-D patients.

Major companies operating in the cardiac resynchronization therapy market are Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Terumo Corporation, Biotronik SE & Co. KG, Lepu Medical Technology (Beijing) Co. Ltd., Integer Holdings Corporation, Merit Medical Systems Inc., LivaNova PLC, MicroPort Scientific Corporation, Sorin Group, Berlin Heart GmbH, EBR Systems Inc., Corvia Medical Inc., Recor Medical, Jarvik Heart Inc., Cardiac Dimensions Inc., Farapulse Inc., Osypka Medical GmbH, Japan Medical Device Corporation, Imricor Medical Systems Inc., Vascular Dynamics Inc., Svelte Medical Systems, Aleva Neurotherapeutics, BioSig Technologies Inc.

North America was the largest region in the cardiac resynchronization therapy market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac resynchronization therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cardiac resynchronization therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cardiac resynchronization therapy market consists of revenues earned by entities by providing services such as patient evaluation and diagnosis, device implantation procedures, device programming, follow-up care, management of complications, patient education, and collaborative care involving a multidisciplinary team. The market value includes the value of related goods sold by the service provider or included within the service offering. The cardiac resynchronization therapy market also includes sales of pacemakers or defibrillators, leads, programmers, accessories, diagnostic tools, patient monitoring devices, and educational materials. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cardiac Resynchronization Therapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cardiac resynchronization therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for cardiac resynchronization therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cardiac resynchronization therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Cardiac Resynchronization Therapy Market Characteristics

3. Cardiac Resynchronization Therapy Market Trends And Strategies

4. Cardiac Resynchronization Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Cardiac Resynchronization Therapy Growth Analysis And Strategic Analysis Framework

6. Cardiac Resynchronization Therapy Market Segmentation

7. Cardiac Resynchronization Therapy Market Regional And Country Analysis

8. Asia-Pacific Cardiac Resynchronization Therapy Market

9. China Cardiac Resynchronization Therapy Market

10. India Cardiac Resynchronization Therapy Market

11. Japan Cardiac Resynchronization Therapy Market

12. Australia Cardiac Resynchronization Therapy Market

13. Indonesia Cardiac Resynchronization Therapy Market

14. South Korea Cardiac Resynchronization Therapy Market

15. Western Europe Cardiac Resynchronization Therapy Market

16. UK Cardiac Resynchronization Therapy Market

17. Germany Cardiac Resynchronization Therapy Market

18. France Cardiac Resynchronization Therapy Market

19. Italy Cardiac Resynchronization Therapy Market

20. Spain Cardiac Resynchronization Therapy Market

21. Eastern Europe Cardiac Resynchronization Therapy Market

22. Russia Cardiac Resynchronization Therapy Market

23. North America Cardiac Resynchronization Therapy Market

24. USA Cardiac Resynchronization Therapy Market

25. Canada Cardiac Resynchronization Therapy Market

26. South America Cardiac Resynchronization Therapy Market

27. Brazil Cardiac Resynchronization Therapy Market

28. Middle East Cardiac Resynchronization Therapy Market

29. Africa Cardiac Resynchronization Therapy Market

30. Cardiac Resynchronization Therapy Market Competitive Landscape And Company Profiles

31. Cardiac Resynchronization Therapy Market Other Major And Innovative Companies

32. Global Cardiac Resynchronization Therapy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cardiac Resynchronization Therapy Market

34. Recent Developments In The Cardiac Resynchronization Therapy Market

35. Cardiac Resynchronization Therapy Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â